CoChat
Sign Up
Cited by 100

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

Wang, Zhenpeng, Tang, Yufei, Xie, Lei, Huang, Aiping, Xue, Chunchun, Gu, Zhen, Wang, Kaiqiang, Zong, Shaoqi·2019·Frontiers in Oncology
DOI 10.3389/fonc.2019.00309PMC PMC6503057
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2019.00309

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram of study inclusion.
Figure 1 Flow diagram of study inclusion.CC BY · PubMed Central
Figure 2 Subgroup analysis of the association between different isoforms of CD44 and OS in patients with colorectal cancer.
Figure 2 Subgroup analysis of the association between different isoforms of CD44 and OS in patients with colorectal cancer.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 99

  1. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
  2. Van Cutsem, 2014, Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol., 25, iii1, 10.1093/annonc/mdu260 · DOI · Paper page
  3. Weiser, 2018, AJCC 8th Edition: colorectal cancer, Ann Surg Oncol., 25, 1454, 10.1245/s10434-018-6462-1 · DOI · Paper page
  4. Pardal, 2003, Morrison: applying the principles of stem-cell biology to cancer, Nat Rev Cancer., 3, 895, 10.1038/nrc1232 · DOI
  5. Liu, 2017, RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer, Clin Cancer Res., 23, 514, 10.1158/1078-0432.ccr-15-1348 · DOI
  6. Singh, 2004, Identification of human brain tumour initiating cells, Nature., 432, 396, 10.1038/nature03128 · DOI
  7. O'Brien, 2007, A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, Nature., 445, 106, 10.1038/nature05372 · DOI
  8. Dalerba, 2007, Phenotypic characterization of human colorectal cancer stem cells, Proc Natl Acad Sci USA., 104, 10158, 10.1073/pnas.0703478104 · DOI
  9. Du, 2008, CD44 is of functional importance for colorectal cancer stem cells, Clin Cancer Res., 14, 6751, 10.1158/1078-0432.ccr-08-1034 · DOI
  10. Nagano, 2004, Mechanism and biological significance of CD44 cleavage, Cancer Sci., 95, 930, 10.1111/j.1349-7006.2004.tb03179.x · DOI · Paper page
  11. Cheng, 2006, Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion, Mol Cell Biol., 26, 362, 10.1128/mcb.26.1.362-370.2006 · DOI
  12. Vigetti, 2008, Hyaluronan-CD44-ERK1/2 regulate human aortic smooth muscle cell motility during aging, J Biol Chem., 283, 4448, 10.1074/jbc.M709051200 · DOI
  13. Naor, 1997, CD44: structure, function, and association with the malignant process, Adv Cancer Res., 71, 241, 10.1016/S0065-230X(08)60101-3 · DOI
  14. Ponta, 2003, CD44: from adhesion molecules to signalling regulators, Nat Rev Mol Cell Biol., 4, 33, 10.1038/nrm1004 · DOI
  15. Negi, 2012, Role of CD44 in tumour progression and strategies for targeting, J Drug Target., 20, 561, 10.3109/1061186x.2012.702767 · DOI
  16. Zoller, 2011, CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?, Nat Rev Cancer., 11, 254, 10.1038/nrc3023 · DOI
  17. Bates, 2001, A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells, Cancer Res., 61, 5275
  18. Fujita, 2002, CD44 signaling through focal adhesion kinase and its anti-apoptotic effect, FEBS Lett., 528, 101, 10.1016/s0014-5793(02)03262-3 · DOI
  19. Wang, 2006, Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer, Arch Otolaryngol Head Neck Surg., 132, 771, 10.1001/archotol.132.7.771 · DOI
  20. Miletti-Gonzalez, 2005, The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer, Cancer Res., 65, 6660, 10.1158/0008-5472.can-04-3478 · DOI
  21. Kim, 2005, Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells, Cancer Res., 65, 686, 10.1158/0008-5472.686.65.3 · DOI
  22. Yu, 1999, Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion, Genes Dev., 13, 35, 10.1101/gad.13.1.35 · DOI
  23. Chen, 2014, Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis, BMC Cancer., 14, 15, 10.1186/1471-2407-14-15 · DOI
  24. Li, 2013, Clinical significance of CD44 variants expression in colorectal cancer, Tumori., 99, 88, 10.1700/1248.13794 · DOI
  25. Wu, 2015, Evaluation of the correlation of KAI1/CD82, CD44, MMP7 and beta-catenin in the prediction of prognosis and metastasis in colorectal carcinoma, Diagn Pathol., 10, 176, 10.1186/s13000-015-0411-0 · DOI
  26. Hong, 2015, Expression of the cancer stem cell markers CD44 and CD133 in colorectal cancer: an immunohistochemical staining analysis, Ann Coloproctol., 31, 84, 10.3393/ac.2015.31.3.84 · DOI
  27. Lugli, 2010, Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer, Br J Cancer., 103, 382, 10.1038/sj.bjc.6605762 · DOI
  28. Jungling, 2002, Expression of CD44v6 has no prognostic value in patients with colorectal cancer, Z Gastroenterol., 40, 229, 10.1055/s-2002-25152 · DOI
  29. Chen, 2014, The prognostic value of CD44 expression in gastric cancer: a meta-analysis, Biomed Pharmacother., 68, 693, 10.1016/j.biopha.2014.08.001 · DOI
  30. Luo, 2016, Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis, Cancer Cell Int., 16, 47, 10.1186/s12935-016-0325-2 · DOI
  31. Li, 2015, Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis, Sci Rep., 5, 13157, 10.1038/srep13157 · DOI
  32. Lin, 2017, The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis, Cancer Cell Int., 17, 8, 10.1186/s12935-016-0376-4 · DOI
  33. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ., 339, b2535, 10.1136/bmj.b2535 · DOI · Paper page
  34. Bhatavdekar, 1998, Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas, Ann Surg Oncol., 5, 495, 10.1007/BF02303641 · DOI
  35. Sokmen, 2001, Prognostic value of CD44 expression in colorectal carcinomas, Anticancer Res., 21, 4121
  36. Ropponen, 1998, Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis, Scand J Gastroenterol., 33, 301, 10.1080/00365529850170900 · DOI
  37. Visca, 2002, Role and prognostic significance of CD44s expression in colorectal cancer, Anticancer Res., 22, 2671
  38. Ngan, 2007, A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer, J Surg Oncol., 95, 652, 10.1002/jso.20638 · DOI
  39. Horst, 2009, Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer, Cancer Invest., 27, 844, 10.1080/07357900902744502 · DOI
  40. Seo, 2015, Prognostic implications of adhesion molecule expression in colorectal cancer, Int J Clin Exp Pathol., 8, 4148
  41. Cai, 2016, Correlation of multiple proteins with clinic-pathological features and its prognostic significance in colorectal cancer with signet-ring cell component, Eur Rev Med Pharmacol Sci., 20, 3358
  42. Mohamed, 2018, The prognostic value of cancer stem cell markers (Notch1, ALDH1, and CD44) in primary colorectal carcinoma, J Gastrointest Cancer., 10.1007/s12029-018-0156-6 · DOI
  43. Qu, 2017, Prognostic value of E-cadherin-, CD44-, and MSH2-associated nomograms in patients with stage II and III colorectal cancer, Transl Oncol., 10, 121, 10.1016/j.tranon.2016.12.005 · DOI
  44. Iseki, 2017, Significance of E-cadherin and CD44 expression in patients with unresectable metastatic colorectal cancer, Oncol Lett., 14, 1025, 10.3892/ol.2017.6269 · DOI
  45. Ribeiro, 2016, KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer, Cancer Biomark., 16, 513, 10.3233/cbm-160592 · DOI
  46. Zavrides, 2005, Prognostic evaluation of CD44 expression in correlation with bcl-2 and p53 in colorectal cancer, Folia Histochem Cytobiol., 43, 31
  47. Huh, 2009, Expression of standard CD44 in human colorectal carcinoma: association with prognosis, Pathol Int., 59, 241, 10.1111/j.1440-1827.2009.02357.x · DOI · Paper page
  48. Choi, 2009, Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma, World J Gastroenterol., 15, 2258, 10.3748/wjg.15.2258 · DOI
  49. Saigusa, 2012, Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy, Int J Oncol., 41, 1643, 10.3892/ijo.2012.1598 · DOI
  50. Fernandez, 2004, CD44s expression in resectable colorectal carcinomas and surrounding mucosa, Cancer Invest., 22, 878, 10.1081/cnv-200039658 · DOI
  51. Vizoso, 2004, Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer, J Cancer Res Clin Oncol., 130, 679, 10.1007/s00432-004-0596-1 · DOI
  52. Saito, 2013, CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer, Oncol Rep., 29, 1570, 10.3892/or.2013.2273 · DOI
  53. Ozawa, 2014, Prognostic significance of CD44 variant 2 upregulation in colorectal cancer, Br J Cancer., 111, 365, 10.1038/bjc.2014.253 · DOI
  54. Kobel, 2004, Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis, Virchows Arch., 445, 456, 10.1007/s00428-004-1095-0 · DOI
  55. Zlobec, 2009, Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer, Histopathology., 55, 564, 10.1111/j.1365-2559.2009.03421.x · DOI
  56. Koretz, 1995, Effect of CD44v6 on survival in colorectal carcinoma, Lancet., 345, 327, 10.1016/S0140-6736(95)90320-8 · DOI
  57. Haruyama, 1999, Clinicopathological significance of the expression of CD44v2 in colorectal cancer, Anticancer Res., 19, 4421
  58. Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med., 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 · DOI
  59. Altman, 2011, How to obtain the confidence interval from a P value, BMJ., 343, d2090, 10.1136/bmj.d2090 · DOI
  60. Sauerbrei, 2018, Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration, J Natl Cancer Inst., 110, 803, 10.1093/jnci/djy088 · DOI
  61. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  62. DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials., 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  63. Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics., 50, 1088, 10.2307/2533446 · DOI · Paper page
  64. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ., 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  65. Katoh, 2015, Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer, Anticancer Res., 35, 239
  66. Ichikawa, 1994, Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer, Pathobiology., 62, 172, 10.1159/000163907 · DOI
  67. Kunimura, 2009, The relationships between loss of standard CD44 expression and lymph node, liver metastasis in T3 colorectal carcinoma, J Gastrointest Cancer., 40, 115, 10.1007/s12029-009-9100-0 · DOI
  68. Wang, 2018, [Expression of stem cell markers CD44 and Lgr5 in colorectal cancer and its relationship with lymph node and liver metastasis], Zhonghua Yi Xue Za Zhi., 98, 2899, 10.3760/cma.j.issn.0376-2491.2018.36.005 · DOI
  69. Isozaki, 1998, Expression of cell adhesion molecule CD44 and sialyl Lewis A in gastric carcinoma and colorectal carcinoma in association with hepatic metastasis, Int J Oncol., 13, 935
  70. Zhao, 2015, CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression, Int J Clin Exp Pathol., 8, 692
  71. Gotley, 1996, Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer, Br J Cancer., 74, 342, 10.1038/bjc.1996.364 · DOI
  72. Gunther, 2002, Prediction of distant metastases after curative surgery for rectal cancer, J Surg Res., 103, 68, 10.1006/jsre.2001.6312 · DOI
  73. Avoranta, 2012, Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence, World J Gastroenterol., 18, 4549, 10.3748/wjg.v18.i33.4549 · DOI
  74. Ismaiel, 2016, Detection of cancer stem cells in colorectal cancer: histopathological and immunohistochemical study, Open Access Maced J Med Sci., 4, 543, 10.3889/oamjms.2016.126 · DOI
  75. Amirghofran, 2008, Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis, J Gastrointest Cancer., 39, 73, 10.1007/s12029-009-9062-2 · DOI
  76. Ishida, 2000, Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma, Surg Today., 30, 28, 10.1007/pl00010042 · DOI
  77. Yamane, 1999, Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer, Oncology., 56, 232, 10.1159/000011970 · DOI
  78. Michl, 2015, Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system, Pathol Res Pract., 211, 601, 10.1016/j.prp.2015.05.006 · DOI
  79. Choi, 2017, Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: clinicopathological significance, Oncol Rep., 38, 1695, 10.3892/or.2017.5790 · DOI
  80. Neumann, 2015, Cancer stem cell markers are associated with distant hematogenous liver metastases but not with peritoneal carcinomatosis in colorectal cancer, Cancer Invest., 33, 354, 10.3109/07357907.2015.1047507 · DOI
  81. Huh, 2014, Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer, Ann Surg., 259, 508, 10.1097/SLA.0b013e31829b3916 · DOI
  82. Jing, 2015, Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases, Int J Oncol., 46, 1582, 10.3892/ijo.2015.2844 · DOI
  83. Rohani, 2017, CD44 standard isoform; not a good marker for colon cancer, Int J Cancer Manag., 10, 5, 10.5812/ijcm.9166 · DOI
  84. Gallatin, 1983, A cell-surface molecule involved in organ-specific homing of lymphocytes, Nature., 304, 30, 10.1038/304030a0 · DOI
  85. Prince, 2007, Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma, Proc Natl Acad Sci USA., 104, 973, 10.1073/pnas.0610117104 · DOI
  86. Hurt, 2008, CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis, Br J Cancer., 98, 756, 10.1038/sj.bjc.6604242 · DOI
  87. Al-Hajj, 2003, Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci USA., 100, 3983, 10.1073/pnas.0530291100 · DOI
  88. Zhang, 2008, Identification and characterization of ovarian cancer-initiating cells from primary human tumors, Cancer Res., 68, 4311, 10.1158/0008-5472.can-08-0364 · DOI
  89. Inoue, 2015, Aberrant splicing of estrogen receptor, HER2, and CD44 genes in breast cancer, Genet Epigenet., 7, 19, 10.4137/geg.s35500 · DOI
  90. Xiaoping, 2015, Expression and significance of CD44 and p-AKT in pancreatic head cancer, World J Surg Oncol., 13, 334, 10.1186/s12957-015-0746-8 · DOI
  91. Biddle, 2013, CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition, PLoS ONE., 8, e57314, 10.1371/journal.pone.0057314 · DOI
  92. Brown, 2011, CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression, J Clin Invest., 121, 1064, 10.1172/jci44540 · DOI
  93. Mashita, 2014, Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer, J Surg Oncol., 110, 745, 10.1002/jso.23705 · DOI
  94. Krishnamachary, 2012, Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer, PLoS ONE., 7, e44078, 10.1371/journal.pone.0044078 · DOI
  95. Ishimoto, 2011, CD44 variant regulatesredox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth, Cancer Cell., 19, 387, 10.1016/j.ccr.2011.01.038 · DOI · Paper page
  96. Barbour, 2003, Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3, Cancer Res., 63, 887
  97. Gunthert, 1991, A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells, Cell., 65, 13, 10.1016/0092-8674(91)90403-L · DOI
  98. Weg-Remers, 1998, Decreased expression of CD44 splicing variants in advanced colorectal carcinomas, Eur J Cancer., 34, 1607, 10.1016/S0959-8049(98)00177-4 · DOI
  99. Katoh, 1994, Characterization of soluble CD44 in the circulation of mice, Levels are affected by immune activity and tumor growth. J Immunol., 153, 3440

Cited by

Sorted by citations

See all 100

Metadata

Authors
Wang, Z., Tang, Y., Xie, L., Huang, A., Xue, C., Gu, Z., Wang, K., & Zong, S.
Venue
Frontiers in Oncology
Publisher
Frontiers Media SA
Published
2019-04-30
Volume
9
ISSN
2234-943X
DOI
10.3389/fonc.2019.00309
PMC
PMC6503057
Cited by
100
References
1
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • National Natural Science Foundation of China
  • Shanghai University of Traditional Chinese Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review